Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Immutep has been granted a new European patent for the treatment of cancer
  • In May 2019, Immutep was granted a European patent to protect its intellectual property for the treatment of cancer and other autoimmune diseases
  • The product, LAG-3, is a protein which is involved in the regulation of the immune system

Biotech company Immutep has been granted a new patent entitled ‘LAG-3 dosage regime for use in the treatment of cancer,’ by the European Patent Office.

This European patent was filed as a divisional application and follows the grant of the European parent patent and two other additional European patents from the same family.

In May 2019, Immutep was granted a new European patent to protect its intellectual property regarding the specific treatment of cancer and other autoimmune diseases.

This new patent provides further intellectual property protection for Immutep’s method of treating cancer by the administration of multiple doses of the LAG-3 protein.

LAG-3, which stands for Lymphocyte Activation Gene-3, is a protein which is involved in the regulation of the immune system.

The protein controls the signalling between specific immune cells, T cells (white blood cell which is developed in the thymus gland) and antigen presenting cells (APC) which are responsible for the adaptive immune response.

Through the binding of soluble LAG-3, APC activation takes place. This leads to LAG-3 activating the antigen presenting cells such as monocytes and dendritic (nerve) cells.

This results in an increase in the number and activation of T cells which is an active immunotherapy mechanism which is important for fighting cancer.

Through these mechanisms, soluble LAG-3 can increase the immune response to cancer antigens.

In T cells, LAG-3 is a co-inhabitant receptor physically associated with the T cell receptor and expressed on activated T cells.

When LAG-3 is expressed on an activated CD8+ T cell (a type of T cell), it binds the same time as the T cell receptor and the LAG-3 binding stops calcium signalling, which leads to a reduction in cytokine (small proteins) production and a decline in the immune response.

Based on these different mechanism actions, Immutep has developed four product candidates that are currently being developed or have been out-licensed to one of Immutep’s partners for development and commercialisation.

IMM by the numbers
More From The Market Herald
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.